Perrigo Ordinary Shares reported $372.1M in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US $ 6324M 584M
Bayer BAYN:GR 7.14B 2.32B
Bristol Myers Squibb BMY:US $ 9210M 33M
Catalent CTLT:US $ 488M 65M
Corcept Therapeutics CORT:US $ 102.07M 9.63M
Dr.Reddys Laboratories DRRD:IN 33.22B 2.56B
Eli Lilly And LLY:US $ 5057.5M 680.4M
Horizon Pharma HZNP:US $ 646.2M 23.99M
JAZZ PHA JAZZ:US $ 808.67M 110.23M
Johnson & Johnson JNJ:US $ 16101M 273M
Lannett LCI:US $ 7.86M 4.78M
Merk MRK:US $ 10895M 328M
Pacira Pharmaceuticals PCRX:US $ 118.78M 3.13M
Perrigo Ordinary Shares PRGO:US $ 372.1M 34.3M
Pfizer PFE:US $ 19071M 3420M
Prestige Brands PBH:US $ 160.12M 11.26M
Supernus Pharmaceuticals SUPN:US $ 149.59M 15.02M
Teva Pharmaceutical TEVA:IT 1.83B 26M
Xeris Pharmaceuticals Inc XERS:US $ 20.5M 4.7M
Zoetis ZTS:US $ 1432M 11M